Better Results For Invega Over Seroquel Could Be Trouble for AstraZeneca
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Johnson & Johnson may be able to increase sales of its atypical antipsychotic Invega (paliperidone extended-release) at the expense of AstraZeneca's Seroquel (quetiapine) by touting positive head-to-head data in acutely ill, hospitalized schizophrenia patients